The Jak-Stat pathway has recently attracted researchers’ attention. This has been motivated by the fact that this pathway is a potential target of future agents for the treatment of myeloproliferative disorders such as: polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. The animation below depicts the Jak-Stat signalling pathway mechanism: As mentioned above, there…
Category Archives: Hematology, cancer chemotherapy and related
Thrombolytic agents: mechanism of action, indications, contraindications and side effects
Thrombolytic agents are used to lyse already formed blood clots in clinical settings where ischemia may be fatal ( acute mycardial infarction, pulmonary embolism, ischemic stroke, and arterial thrombosis). Very precise indications rule the use of these drugs, which are not free from serious side effects ( bleeding). Outline: Mechanism of action of thrombolytic therapy…
COGENT trial: no clopidogrel-PPIs interaction
According to the results of the COGENT trial, the combination of the antiplatelet clopidogrel and the PPI omeprazole does not produce clinically relevant cardiovascular interactions.
Cancer chemotherapy: PPT presentations
The PowerPoint files in this posts have been shared by R. Senthil Kumar M.D. , Dean of Basic Sciences and Pharmacology Professor at St. Matthew’s University School of Medicine. If you are interested in contributing to this blog, just send an e-mail to pharmamotion@gmail.com PPT 1: Introduction to cancer chemotherapy Download PPT file: Cancer Chemotherapy…
Serotonin 5-HT3-receptor antagonists: pharmacokinetics, MOA, indications and adverse effects
This posts overviews the general characteristics, pharmacokinetics, mechanism of action, dosing, indications and adverse effects profile of serotonin 5-HT3-receptor antagonists. These drugs are being increasingly used for the prevention of chemotherapy induced nausea and vomiting as well as antiemetic prophylaxis of post-operative and post-radiation nausea and vomiting.
FDA video on erlotinib (Tarceva) adverse effects
FDA video warning on gastrointestinal dermatologic and ophthalmic side effects of erlotinib (Tarceva).
Rituximab (Rituxan, MabThera): first line treatment for chronic lymphocytic leukemia
The UK’s National Institute for Health and Clinical Excellence (NICE) issued yesterday a guidance on the use of rituximab as first line treatment for chronic lymphocytic leukemia.
PPIs reduce the effectiveness of clopidogrel (Plavix)
Pharmamotion has now a new page containing updates on clopidogrel – PPI interactions. The latest edition of the monthly newsletter from the Medicines and Healthcare products Regulatory Agency has issued a drug safety advice on the interaction between the antiplatelet drug clopidogrel (Plavix) and PPIs. They conclude that available data supports a clinically significant interaction…
FDA approves bevacizumab (Avastin) for glioblastoma multiforme
Prescribing information, mechanism of action, approved indications and videos on Avastin (bevacizumab) for glioblastoma multiforme.
Overview on monoclonal antibody therapy: PPT, images and videos
This post intends to be a brief and readable overview on what monoclonal antibodies (mAbs) are and some examples of their clinical applications. The following slideshow is a clear and accurate introduction on the topic: (ignore the first slide error message and move to the second)
Lectures on antiemetics pharmacology: MOA, indications, side effects and new drugs reviewed
PowerPoint slideshows on pharmacology of antiemetics .MOA, dosing, indications and side effects of: serotonin and dopamine antagonists, anticholinergics, new antiemetics.
NICE recommends sunitinib (Sutent) for the first-line treatment of metastatic renal cancer
NICE (UK) recommends the tyrosine kinase inhibitor sunitinib (Sutent) first line treatment of metastatic renal cell carcinoma. Implications for patients that are on immunotherapy
Warfarin dosing: the role of genes
Warfarin dosing: the genes VKORC1, CYP2C9, CYP4F2 are determinants in the dosing of warfarin. Role in clinical practice of pharmacogenomics: genetic testing to guide warfarin therapy.
Vorinostat MSD for cutaneous T-cell lymphoma. MSD withdraws marketing application
Excerpts from the EMEA press release (dated 17th February) on the withdrawal of the marketing application for Vorinostat MSD: The European Medicines Agency (EMEA) has been formally notified by Merck Sharp & Dohme Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vorinostat MSD (vorinostat), 100 mg hard…
